tiprankstipranks
Trending News
More News >

OptimizeRx price target raised to $18 from $13 at B. Riley

B. Riley raised the firm’s price target on OptimizeRx (OPRX) to $18 from $13 and keeps a Buy rating on the shares. OptimizeRx reported “strong” Q1 results, beating consensus estimates on sales and adjusted EBITDA, while raising fiscal 2025 guidance for sales and adjusted EBITDA, the analyst tells investors in a research note. The firm views the potential elimination of direct-to-consumer pharmaceutical TV advertising to be a tailwind, driving more spend toward OptimizeRx’s targeted marketing approach, and remains confident in the company’s future outlook.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue